Anavex's Alzheimer's drug rejection sends stock into a tailspin

Anavex Life Sciences suffered a major blow on March 25 when it withdrew its application for EU approval of blarcamesine, an Alzheimer's treatment. The company's stock plunged sharply, losing between 18% and 35% in early trading before recovering slightly. Investors reacted strongly to the setback, which delays the drug's path to market. The European Medicines Agency (EMA) had signalled it would not approve blarcamesine in its current form. Regulators questioned the existing data, suggesting further trials or detailed analyses might be needed. This decision often hints at similar challenges with the U.S. Food and Drug Administration (FDA), raising concerns about the drug's future revenue.

Earlier trials had shown promise, with Phase 2b/3 results reporting a 36% improvement in Alzheimer's symptoms and a reduction in brain atrophy. Despite this, the EMA's rejection forced Anavex to pull its marketing application, pushing back commercialisation plans. The stock's decline left it nearly 50% below its year-to-date peak, though it stabilised at around $2.845 by March 26. Anavex remains financially stable, holding $131 million in cash and no debt—enough to fund operations for over three years. Analysts still rate the stock a 'Moderate Buy,' with a $22 price target, implying potential for a ninefold increase. However, the recent drop pushed its 14-day relative strength index into the mid-20s, a sign of oversold conditions.

The withdrawal of blarcamesine's EU application marks a significant delay for Anavex. The company now faces potential further trials before resubmitting, while investors weigh the stock's sharp decline against its long-term prospects. With strong cash reserves, the firm retains time to address regulatory concerns.